azd2373
Nucleic acidexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Feb 13, 2020 (NCT04269031)
Timeline
Indications
Mechanism of action
- Apolipoprotein L1INHIBITOR
APOL1 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314860 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07154901 | Phase 1 | Aug 18, 2025 | AstraZeneca |
| NCT06824987 | Phase 2 | Mar 5, 2025 | AstraZeneca |
| NCT05351047 | Phase 1 | Apr 4, 2022 | AstraZeneca, Parexel |
| NCT04269031 | Phase 1 | Feb 13, 2020 | AstraZeneca, Parexel |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 4 | 4 | 2 | 2020 |
| Parexel | For profit | 2 | 0 | 1 | 2020 |
2 organizations
Page 1 / 1